270 related articles for article (PubMed ID: 37623461)
21. Autoimmune Pituitary Disease: New Concepts With Clinical Implications.
Yamamoto M; Iguchi G; Bando H; Kanie K; Hidaka-Takeno R; Fukuoka H; Takahashi Y
Endocr Rev; 2020 Apr; 41(2):. PubMed ID: 31513261
[TBL] [Abstract][Full Text] [Related]
22. Autoimmune phenomena involving the pituitary gland in children: New developing data about diagnosis and treatment.
Romano A; Rigante D; Cipolla C
Autoimmun Rev; 2019 Oct; 18(10):102363. PubMed ID: 31401342
[TBL] [Abstract][Full Text] [Related]
23. The early-stage clinical course of anti-pituitary-specific transcription factor-1 hypophysitis diagnosed post-immune checkpoint inhibitor treatment: A case with review of literature.
Urai S; Tomofuji S; Bando H; Kanzawa M; Yamamoto M; Fukuoka H; Tsuda M; Iguchi G; Ogawa W
J Neuroendocrinol; 2024 Jun; 36(6):e13395. PubMed ID: 38631695
[TBL] [Abstract][Full Text] [Related]
24. Review on Recent Topics in Hypophysitis.
Sugihara H
J Nippon Med Sch; 2017; 84(5):201-208. PubMed ID: 29142180
[TBL] [Abstract][Full Text] [Related]
25. HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis.
Heaney AP; Sumerel B; Rajalingam R; Bergsneider M; Yong WH; Liau LM
J Clin Endocrinol Metab; 2015 Nov; 100(11):4092-7. PubMed ID: 26317559
[TBL] [Abstract][Full Text] [Related]
26. Two Cases of anti-PIT-1 Hypophysitis Exhibited as a Form of Paraneoplastic Syndrome not Associated With Thymoma.
Kanie K; Iguchi G; Inuzuka M; Sakaki K; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Taniguchi T; Ogawa W; Takahashi Y
J Endocr Soc; 2021 Mar; 5(3):bvaa194. PubMed ID: 33506159
[TBL] [Abstract][Full Text] [Related]
27. Anti-pituitary antibodies as a marker of autoimmunity in pituitary glands.
Iwama S; Arima H
Endocr J; 2020 Nov; 67(11):1077-1083. PubMed ID: 33055452
[TBL] [Abstract][Full Text] [Related]
28. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.
Caturegli P; Di Dalmazi G; Lombardi M; Grosso F; Larman HB; Larman T; Taverna G; Cosottini M; Lupi I
Am J Pathol; 2016 Dec; 186(12):3225-3235. PubMed ID: 27750046
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitor-related hypophysitis.
Mizukoshi T; Fukuoka H; Takahashi Y
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101668. PubMed ID: 35562229
[TBL] [Abstract][Full Text] [Related]
30. Two Cases of Atezolizumab-Induced Hypophysitis.
Kanie K; Iguchi G; Bando H; Fujita Y; Odake Y; Yoshida K; Matsumoto R; Fukuoka H; Ogawa W; Takahashi Y
J Endocr Soc; 2018 Jan; 2(1):91-95. PubMed ID: 29362727
[TBL] [Abstract][Full Text] [Related]
31. An autopsy case study of lymphocytic hypophysitis induced by nivolumab treatment for esophageal malignant melanoma.
Okabe N; Kobayashi T; Furuse J; Fujiwara M; Kamma H
Pathol Int; 2021 Dec; 71(12):831-836. PubMed ID: 34506687
[TBL] [Abstract][Full Text] [Related]
32. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
33. How we treat endocrine complications of immune checkpoint inhibitors.
Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
35. The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events.
Mihic-Probst D; Reinehr M; Dettwiler S; Kolm I; Britschgi C; Kudura K; Maggio EM; Lenggenhager D; Rushing EJ
Immunobiology; 2020 Sep; 225(5):152009. PubMed ID: 32962812
[TBL] [Abstract][Full Text] [Related]
36. A COMMON PITUITARY AUTOANTIBODY IN TWO PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-MEDIATED HYPOPHYSITIS: ZCCHC8.
Leiter A; Gnjatic S; Fowkes M; Kim-Schulze S; Laface I; Galsky MD; Gallagher EJ
AACE Clin Case Rep; 2020; 6(4):e151-e160. PubMed ID: 32671216
[TBL] [Abstract][Full Text] [Related]
37. The novel concept of "Onco-Immuno-Endocrinology" led to the discovery of new clinical entity "paraneoplastic autoimmune hypophysitis".
Takahashi Y
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101663. PubMed ID: 35525821
[TBL] [Abstract][Full Text] [Related]
38. Cancer immunotherapy-associated hypophysitis.
Solinas C; Porcu M; De Silva P; Musi M; Aspeslagh S; Scartozzi M; Willard-Gallo K; Mariotti S; Saba L
Semin Oncol; 2018 Jun; 45(3):181-186. PubMed ID: 30352754
[TBL] [Abstract][Full Text] [Related]
39. Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice.
Chiloiro S; Russo F; Tartaglione T; Capoluongo ED
J Pers Med; 2021 Oct; 11(10):. PubMed ID: 34683167
[TBL] [Abstract][Full Text] [Related]
40. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
